Deep Learning in Drug Discovery and Diagnostics, 2017 - 2035

  • ID: 4142616
  • Report
  • Region: Global
  • 235 Pages
  • Roots Analysis
1 of 5
By 2035, Deep Learning Solutions Can Result in Annual Savings of Over USD 35 Billion in the Diagnostics Segment Alone

FEATURED COMPANIES

  • 23andMe
  • ClearView Diagnostics
  • gener8tor
  • Jvion
  • Notable Labs
  • Standigm
  • MORE

The “Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035” report examines the current landscape and future outlook of the growing market of deep learning solutions within the healthcare domain. Primarily driven by the big data revolution, deep learning algorithms have emerged as a novel solution to generate relevant insights from medical data.

This continuing shift towards digitalization of healthcare system has been backed by a number of initiatives taken by the government, and has also sparked the interest of several industry / non-industry players. The involvement of global technology companies and their increasing collaborations with research institutes and hospitals are indicative of the research intensity in this field. At the same time, the pharma giants have been highly active in adopting the digital models. Companies such as AstraZeneca, Pfizer and Novartis continue to evaluate the digital health initiatives across drug discovery, clinical trial management and medical diagnosis.

Some notable examples of such digital health initiatives include GSK and Pfizer’s collaboration with Apple for the use of the latter’s research kit in clinical trials, Biogen’s partnership with Fitbit for using smart wearables in clinical trial management, and Teva Pharmaceuticals’ partnership with American Well to use Smart Inhalers for patients with asthma and COPD.

Backed by funding from several Venture Capital firms and strategic investors, deep learning has emerged as one of the most widely explored initiatives within digital healthcare. The current generation of deep learning models are flexible and have the ability to evolve and become more efficient over time. Despite being a relatively novel field of research, these models have already demonstrated significant potential in the healthcare industry.

One of the key objectives of this study was to identify the various deep learning solutions that are currently available / being developed to cater to unmet medical needs, and also evaluate the future prospects of deep learning within the healthcare industry. These solutions are anticipated to open up significant opportunities in the field of drug discovery and diagnostics as the healthcare industry gradually shifts towards digital solutions.

In addition to other elements, the study covers the following:

The current status of the market with respect to key players, specific applications and the therapeutic areas in which these solutions can be applied.

The various initiatives that are being undertaken by technology giants, such as IBM, Google, Facebook, Microsoft, NVIDIA and Samsung. The presence of these stakeholders signifies the opportunity and the impact that these solutions are likely to have in the near future. Specifically, we have presented a comparative analysis of the deep learning solutions developed by IBM and Google.

Detailed profiles of some of the established, as well as emerging players in the industry, highlighting key technology features, primary applications and other relevant information.

The impact of venture capital funding in this area. It is important to mention that since the industry has witnessed the emergence of several start-ups, funding is a key enabler that is likely to drive both innovation and product development in the coming years.

An elaborate valuation analysis of companies that are involved in applying deep learning in drug discovery and diagnostics. We built a multi-variable dependent valuation model to estimate the current valuation of a number of companies focused in this domain.

Future growth opportunities and likely impact of deep learning in the drug discovery and diagnostics domains. The forecast model, backed by robust secondary research and credible inputs from primary research, was primarily based on the likely time-saving and its associated cost-saving opportunity to the healthcare system.

For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Mausumi Acharya (CEO, Advenio Technosys), Carla Leibowitz (Head of Strategy and Marketing, Arterys) and Deekshith Marla (CTO, Arya.ai).

Example Highlights

During our research, we identified close to 100 industry / non-industry players that are exploring their proprietary deep learning based technologies in drug discovery and diagnostics. A majority of these companies (61%) were founded post 2010. In fact, between 2013 and 2016 alone, the industry saw the emergence of 50 startups in this field.

More than 55% of the companies working in this space are applying their deep learning models for diagnostic purposes. Of these, 78% of the companies offer solutions for medical imaging analysis. Notable examples include (in alphabetical order) Arterys, AvalonAI, Bay Labs, Behold.ai, Butterfly Network, CAMELOT biomedical systems, Cyrcadia Health, Enlitic, iCarbonX, Lunit and Zebra Medical Vision.

On the other hand, close to 35% of the companies engaged in this domain are focused on applying deep learning models in drug discovery. 57% of these companies provide deep learning powered drug discovery platforms. Examples of players in this segment include (in alphabetical order) Atomwise, Benevolent.ai, BERG Health, Cloud Pharmaceuticals, Cyclica, Hummingbird Bioscience, InSilico Medicine, Mind the Byte, Molplex Pharmaceutical, nference, Numedii, Numerate, Standigm, twoXAR, Verge Genomics, Vium and SparkBeyond.

In addition, there are companies that are focused in applying deep learning in both drug discovery as well as diagnostics. Examples of such companies include (in alphabetical order) 23andMe, Appistry, Deep Genomics, Desktop Genetics, Globavir Biosciences, Google, IBM, SolveBio and Wuxi NextCODE.

During the last three years, heavy investments have been made in this domain. Of the overall amount invested in last 10 years (USD 1.8 billion), USD 1.6 billion was invested into deep learning initiatives in and after 2014. There are several recent examples. iCarbonX raised USD 214 million in three funding rounds (January 2016, April 2016 and July 2016), Flatiron Health received USD 175 million in Series C funding (January 2016), LAM Therapeutics witnessed funding of USD 40 million (February 2016), and Human Longevity closed a Series B funding round amounting to USD 220 million (April 2016)..

In the drug discovery segment, the deep learning solutions have shown to significantly reduce the cost and time spent in bringing a drug to the market. Taking a drug from discovery stage to the market is known to cost up to USD 2.5 billion and takes, on an average, close to 12 years. Deep learning models are likely to save as much as 50% of this cost and save a significant amount of time. By 2035, we have predicted annual cost savings of over USD 100 billion for the global healthcare system.

The adoption of deep learning models in diagnostics is also likely to provide several cost and time saving opportunities. According to our estimates, by 2035, deep learning solutions can result in annual savings of over USD 35 billion in the diagnostics segment alone. The activity is likely to be relatively more prominent in the high income countries in the near term. However, in the long term, the low radiologist to patient ratio in middle income countries is likely to provide ample growth opportunities in these countries.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analyst's opinion reports

While the focus has been on forecasting the market over the coming two decades, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the report. It offers a high level view on where the deep learning market for drug discovery and diagnostics is headed in the long term.

Chapter 3 is an introductory chapter that presents details on the digital revolution in the medical industry. It elaborates on the growth of artificial intelligence and machine learning tools, such as deep learning algorithms, along with a discussion on their potential applications in solving some of the key challenges faced by the healthcare industry. The chapter also gives an overview on the rise of big data and its role in providing personalized and evidence based care to patients.
 
Chapter 4 includes information on close to 100 companies that are evaluating potential applications of their proprietary deep learning solutions in the healthcare industry. The classification system used for these solutions was based on their application areas. These include drug discovery, diagnostics, clinical trial management and drug adherence programs. In addition, we have highlighted specific geographical pockets that we identified as innovation hubs in this sector.

Chapter 5 provides detailed profiles of some of the key stakeholders in this space with detailed information on their technologies, funding, collaborations and partnerships, intellectual capital, awards and recognition and activity on social media.

Chapter 6 presents a case study on two technology giants in this field, namely IBM and Google. It provides a detailed description of the initiatives being undertaken by these companies to explore the applications of deep learning in the medical field. In addition, the chapter provides a comparison of the two companies based on their respective deep learning expertise, and partnerships and acquisitions.

Chapter 7 provides information on the various investments that have been made into this industry. Our analysis revealed interesting insights on the growing interest of venture capitalists and other stakeholders in this market. In addition, we identified some of the key investors in this market.

Chapter 8 presents detailed projections related to the growth of the deep learning industry in healthcare from 2017 to 2035. To quantify the opportunity for deep learning in the drug discovery space, we have provided optimistic and conservative forecast scenarios, along with our base forecast to account for the uncertainties associated with the adoption of these technologies. The insights presented in this chapter are backed by data from close to 50 countries and highlights the opportunity for deep learning companies in diagnostics within the same regions.

Chapter 9 features a comprehensive valuation analysis of the companies that are developing deep learning solutions for applications in drug discovery and diagnostics. The chapter provides insights based on a multi-variable dependent valuation model. The model is based on the future potential of the companies’ technologies, their current popularity, funding received, year of establishment and the employed workforce in these companies.

Chapter 10 presents the opinions expressed by selected key opinion leaders on the applications and challenges associated with deep learning in the healthcare sector. The chapter provides key takeaways from presentations and videos of these experts, highlighting the future opportunity for these models within the healthcare industry.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. We have presented the details of our discussions with Mausumi Acharya (CEO, Advenio Technosys), Carla Leibowitz (Head of Strategy and Marketing, Arterys), and Deekshith Marla (CTO, Arya.ai).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures in the report. In addition, the chapter includes a detailed analysis of the survey conducted with several companies to estimate the opportunity for deep learning in drug discovery and diagnostics.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 23andMe
  • ClearView Diagnostics
  • gener8tor
  • Jvion
  • Notable Labs
  • Standigm
  • MORE

1. PREFACE
    1.1. Scope of the Report
    1.2. Research Methodology
    1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
    3.1. Humans, Machines and Intelligence
    3.2. Artificial Intelligence
    3.3. The Science of Learning
        3.3.1. Teaching Machines
            3.3.1.1. Machines for Computing
            3.3.1.2. Understanding Human Brain: Way to Artificial Intelligence
    3.4. The Big Data Revolution
        3.4.1. Big Data: An Introduction
        3.4.2. Big Data: Internet of Things (IoT)
        3.4.3. Big Data: A Growing Trend
        3.4.4. Big Data: Application Areas
            3.4.4.1. Big Data Analytics in Healthcare: Collaborating For Value
            3.4.4.2. Machine Learning
            3.4.4.3. Deep Learning: The Amalgamation of Machine Learning and Big Data
    3.5. Deep Learning in Healthcare
        3.5.1. Personalized Medicine
        3.5.2. Lifestyle Management
        3.5.3. Wearable Devices
        3.5.4. Drug Discovery
        3.5.5. Clinical Trial Management
        3.5.6. Diagnostics
 
4. MARKET OVERVIEW
    4.1. Chapter Overview
    4.2. Deep Learning in Drug Discovery and Diagnostics: Market Landscape
        4.2.1. Deep Learning in Drug Discovery and Diagnostics: Distribution by Specialization
        4.2.2. Deep Learning in Drug Discovery and Diagnostics: Distribution by Geographical Location
        4.2.3. Deep Learning in Drug Discovery and Diagnostics: Distribution by Year of Establishment
    4.3. Deep Learning in Drug Discovery
        4.3.1. Deep Learning in Drug Discovery: Distribution by Type of Solution
        4.3.2. Deep Learning in Drug Discovery: Distribution by Area of Focus
        4.3.3. Deep Learning in Drug Discovery: Distribution by Therapeutic Area
        4.3.4. Deep Learning in Drug Discovery: Regional Mapping
    4.4. Deep Learning in Diagnostics
        4.4.1. Deep Learning in Diagnostics: Distribution by Type of Solution
        4.4.2. Deep Learning in Diagnostics: Distribution by Type of Input Data
        4.4.3. Deep Learning in Diagnostics: Distribution by Therapeutic Area
        4.4.4. Deep Learning in Diagnostics: Regional Mapping
    4.5. Deep Learning in Drug Discovery and Diagnostics
        4.5.1. Deep Learning in Drug Discovery and Diagnostics: Regional Mapping
    4.6. Deep Learning in Drug Discovery and Diagnostics: Non-Industry Players
 
5. COMPANY PROFILES
    5.1. Chapter Overview
    5.2. Advenio Technosys
        5.2.1. Company Overview
        5.2.2. Technology and Services
        5.2.3. Venture Funding
        5.2.4. Intellectual Capital
        5.2.5. Awards and Achievements
        5.2.6. Social Media Activity
    5.3. AiCure
        5.3.1. Company Overview
        5.3.2. Technology and Services
        5.3.3. Venture Funding
        5.3.4. Intellectual Capital
        5.3.5. Awards and Achievements
        5.3.6. Social Media Activity
    5.4. Atomwise
        5.4.1. Company Overview
        5.4.2. Technology and Services
        5.4.3. Venture Funding
        5.4.4. Intellectual Capital
        5.4.5. Social Media Analysis
    5.5. BenevolentAI
        5.5.1. Company Overview
        5.5.2. Technology and Services
        5.5.3. Venture Funding
        5.5.4. Social Media Activity
    5.6. Butterfly Network
        5.6.1. Company Overview
        5.6.2. Technology and Services
        5.6.3. Venture Funding
        5.6.4. Intellectual Capital
        5.6.5. Awards and Achievements
        5.6.6. Social Media Activity
    5.7. Enlitic
        5.7.1. Company Overview
        5.7.2. Technology and Services
        5.7.3. Venture Funding
        5.7.4. Intellectual Property
        5.7.5. Awards and Achievements
        5.7.6. Social Media Activity
    5.8. Human Longevity
        5.8.1. Company Overview
        5.8.2. Technology and Services
        5.8.3. Venture Funding
        5.8.4. Intellectual Capital
        5.8.5. Awards and Achievements
        5.8.6. Social Media Activity
    5.9. InSilico Medicine
        5.9.1. Company Overview
        5.9.2. Technology and Services
        5.9.3. Venture Funding
        5.9.4. Intellectual Capital
        5.9.5. Awards and Achievements
        5.9.6. Social Media Activity
    5.10. twoXAR
        5.10.1. Company Overview
        5.10.2. Technology and Services
        5.10.3. Venture Funding
        5.10.4. Intellectual Capital
        5.10.5. Social Media Activity
    5.11. Zebra Medical Vision
        5.11.1. Company Overview
        5.11.2. Technology and Services
        5.11.3. Venture Funding
        5.11.4. Intellectual Capital
        5.11.5. Social Media Activity
 
6. CASE STUDY: IBM WATSON VERSUS GOOGLE DEEPMIND
    6.1. Chapter Overview
    6.2. IBM
        6.2.1. Company Overview
        6.2.2. Financial Information
        6.2.3. IBM Watson
    6.3. Google
        6.3.1. Company Overview
        6.3.2. Financial Information
        6.3.3. Google DeepMind
    6.4. IBM v/s Google: Artificial Intelligence Acquisitions Portfolio
    6.5. IBM v/s Google: Healthcare Partnerships and Collaborations
    6.6. IBM v/s Google: Future Outlook and Primary Concerns
 
7. CAPITAL INVESTMENTS AND FUNDING
    7.1. Chapter Overview
    7.2. Deep Learning Market: Funding Instances
        7.2.1. Funding Instances: Distribution by Year
        7.2.2. Funding Instances: Distribution by Type of Funding
        7.2.3. Leading Deep Learning Companies: Evaluation by Number of Funding Instances
        7.2.4. Leading VC Firms / Investors: Evaluation by Number of Funding Instances
 
8. OPPORTUNITY ANALYSIS
    8.1. Chapter Overview
    8.2. Opportunity for Deep Learning in Drug Discovery
        8.2.1. Forecast Methodology
        8.2.2. Key Assumptions
        8.2.3. Overall Deep Learning Market in Drug Discovery, 2017-2035
        8.2.4. Comparative Summary
    8.3. Opportunity for Deep Learning in Diagnostics
        8.3.1. Forecast Methodology
        8.3.2. Key Assumptions
        8.3.3. Overall Deep Learning Market in Diagnostics, 2017-2035
    8.4. Overall Deep Learning Market in Drug Discovery and Diagnostics, 2017-2035
 
9. COMPANY VALUATION ANALYSIS
    9.1. Chapter Overview
    9.2. Company Valuation: Methodology
    9.3. Company Valuation: Categorization by Multiple Parameters
        9.3.1. Categorization by Twitter Score
        9.3.2. Categorization by Followers Score
        9.3.3. Categorization by Google Hits Score
        9.3.4. Categorization by Uniqueness Score
        9.3.5. Categorization by Website Score
        9.3.6. Categorization by Awards Score
        9.3.7. Categorization by Weighted Average Score
 
10. DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS
    10.1. Chapter Overview
    10.2. Industry Experts
        10.2.1. Alex Jaimes, CTO, AiCure
        10.2.2. Jeremy Howard, Founder, Enlitic
        10.2.3. Riley Doyle, CEO, Desktop Genomics
    10.3. University and Hospital Experts
        10.3.1. Dr. Steven Alberts, Chairman of Medical Oncology, Mayo Clinic
        10.3.2. Neil Lawrence, Professor, University of Sheffield
        10.3.3. Yoshua Bengio, Professor, Université de Montréal
    10.4. Venture Capital Experts
        10.4.1. Robert Perl, CEO, Permanente Medical Group; Vinod Khosla, CEO, Khosla Ventures; Abraham Verghese, Professor, Stanford School of Medicine
    10.5. Other Expert Opinions
 
11. CONCLUSION
    11.1. Big Data and Deep Learning are Touted as the Next Big Thing in Digital Healthcare
    11.2. The Field is Witnessing Rising Interest from Technology and Pharmaceutical Giants
    11.3. Drug Discovery and Diagnostics have Emerged as the Major Application Areas for Deep Learning in Healthcare
    11.4. Start-ups, Backed by Venture Capital Investors, are Driving Innovation in the Market
    11.5. The Applications of Deep Learning are Expected to Result in Significant Time and Cost Savings
    11.6. Data Sharing and Security Pose the Biggest Hurdles to the Implementation of Deep Learning Solutions
    11.7. Certain Regulatory and Socio-Economic Concerns have Emerged as Additional Roadblocks in this Domain
 
12. INTERVIEW TRANSCRIPTS
    12.1. Mausumi Acharya, CEO, Advenio Technosys
    12.2. Carla Leibowitz, Head of Strategy and Marketing, Arterys
    12.3. Deekshith Marla, CTO, Arya.ai and Sanjay Bhadra, COO, Arya.ai
 
13. APPENDIX 1: TABULATED DATA
 
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Observational Learning: Key Stages of Learning
Figure 3.2 Understanding Neurons and the Human Brain: Key Scientific Contributors
Figure 3.3 Big Data: The Three V’s
Figure 3.4 Internet of Things: Illustrative Framework
Figure 3.5 Internet of Things: Applications in Healthcare
Figure 3.6 Big Data: Google Trends
Figure 3.7 Big Data: Application Areas
Figure 3.8 Big Data: Opportunities in Healthcare
Figure 3.9 Machine Learning Algorithm: Workflow
Figure 3.10 Machine Learning Algorithms: Timeline
Figure 3.11 Neural Networks: Architecture
Figure 3.12 Deep Learning: Image Recognition
Figure 3.13 Google Trends: Artificial Intelligence v/s Machine Learning v/s Deep Learning v/s Cognitive Computing
Figure 3.14 Google Trends: Popular Keywords (Deep Learning)
Figure 3.15 Deep Learning Frameworks: Relative Performance
Figure 3.16 Personalized Medicine: Applications in Healthcare
Figure 4.1 Deep Learning in Drug Discovery and Diagnostics: Distribution by Specialization and Type
Figure 4.2 Deep Learning in Drug Discovery and Diagnostics: Distribution by Geographical Location and Area of Specialization
Figure 4.3 Deep Learning in Drug Discovery and Diagnostics: Distribution by Founding Year and Specialization
Figure 4.4 Deep Learning in Drug Discovery: Distribution by Type of Solution
Figure 4.5 Deep Learning in Drug Discovery: Distribution by Focus Area
Figure 4.6 Deep Learning in Drug Discovery: Distribution by Therapeutic Area
Figure 4.7 Deep Learning in Drug Discovery: Regional Mapping
Figure 4.8 Deep Learning in Diagnostics: Distribution by Type of Solution
Figure 4.9 Deep Learning in Diagnostics: Distribution by Type of Input Data
Figure 4.10 Deep Learning in Diagnostics: Distribution of Service Providers by Key Modifications
Figure 4.11 Deep Learning in Diagnostics: Distribution by Therapeutic Area
Figure 4.12 Deep Learning in Diagnostics: Regional Mapping
Figure 4.13 Deep Learning in Drug Discovery and Diagnostics: Geographical Distribution
Figure 4.14 Deep Learning in Drug Discovery and Diagnostics, Non-Industrial Players: Regional Mapping
Figure 5.1 Advenio Technosys: Company Overview
Figure 5.2 Advenio Technosys: Social Media Analysis
Figure 5.3 AiCure: Company Overview
Figure 5.4 AiCure: Social Media Analysis
Figure 5.5 Atomwise: Company Overview
Figure 5.6 BenevolentAI: Company Overview
Figure 5.7 BenevolentAI: Social Media Analysis
Figure 5.8 Butterfly Network: Company Overview
Figure 5.9 Butterfly Network: Social Media Analysis
Figure 5.10 Enlitic: Company Overview
Figure 5.11 Enlitic: Social Media Analysis
Figure 5.12 Human Longevity: Company Overview
Figure 5.13 Human Longevity: Social Media Analysis
Figure 5.14 InSilico Medicine: Company Overview
Figure 5.15 InSilico Medicine: Social Media Analysis
Figure 5.16 twoXAR: Company Overview
Figure 5.17 twoXAR: Social Media Analysis
Figure 5.18 Zebra Medical Vision: Company Overview
Figure 5.19 Zebra Medical Vision: Social Media Analysis
Figure 6.1 IBM: Annual Revenues, 2011-Q3 2016 (USD Billion)
Figure 6.2 Alphabet: Annual Revenues, 2011-Q3 2016 (USD Billion)
Figure 6.3 IBM versus Google: Acquisition Trend (Artificial Intelligence), 2011-2016
Figure 7.1 Funding Instances: Distribution by Year, 2007-2016
Figure 7.2 Funding Instances: Amount Invested Per Year (USD Million), 2007-2016
Figure 7.3 Funding Instances: Distribution by Type of Funding, 2007-2016
Figure 7.4 Funding Instances: Distribution by Total Amount Invested in Each Category, 2007-2016 (USD Million)
Figure 7.5 Leading Companies: Evaluation by Number of Funding Instances
Figure 7.6 Leading VC Firms: Evaluation by Number of Instances
Figure 8.1 Drug Approval: Historical Data, 2005-2015
Figure 8.2 Opportunity for Deep Learning in Drug Discovery: Future Market Scenarios
Figure 8.3 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Base Scenario (USD Billion)
Figure 8.4 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Base Scenario (USD Billion)
Figure 8.5 Deep Learning Market in Drug Discovery (2017-2035): Market Scenarios (USD Billion)
Figure 8.6 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), High Income Countries
Figure 8.7 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), Middle Income Countries
Figure 8.8 Deep Learning in Diagnostics: Global Distribution of Radiology Images
Figure 8.9 Deep Learning in Diagnostics: Deep Learning Efficiency Profile
Figure 8.10 Deep Learning Market in Diagnostics, Short-Midterm (2017-2026) (USD Billion)
Figure 8.11 Deep Learning Market in Diagnostics, Long Term (2026-2035): Base Scenario (USD Billion)
Figure 8.12 Deep Learning Market in Diagnostics: Market Distribution
Figure 8.13 Overall Deep Learning Market in Drug Discovery and Diagnostics, (2017-2035): Base Scenario (USD Billion)
Figure 9.1 Company Valuation Analysis: A/F Ratio, Input Dataset
Figure 9.2 Company Valuation Analysis: A/Y Ratio, Input Dataset
Figure 9.3 Company Valuation Analysis: A/E Ratio, Input Dataset
Figure 9.4 Company Valuation Analysis: Categorization by Tweets Score
Figure 9.5 Company Valuation Analysis: Categorization by Followers Score
Figure 9.6 Company Valuation Analysis: Categorization by Google Hits Score
Figure 9.7 Company Valuation Analysis: Categorization by Uniqueness Score
Figure 9.8 Company Valuation Analysis: Categorization by Website Score
Figure 9.9 Company Valuation Analysis: Categorization by Awards Score
Figure 9.10 Company Valuation Analysis: Categorization by Weighted Average Score
Figure 9.11 Company Valuation Analysis: Unicorns in Deep Learning
Figure 11.1 Deep Learning Market in Drug Discovery and Diagnostics, (2017-2035): Base Scenario (USD Billion)

List of Tables
Table 3.1 Machine Learning: A Brief History
Table 4.1 Drug Discovery and Diagnostics: Deep Learning Service Providers
Table 4.2 Deep Learning Industry Players: Drug Discovery
Table 4.3 Deep Learning Industry Players: Diagnostics
Table 4.4 Deep Learning Industry Players: Drug Discovery and Diagnostics
Table 4.5 Deep Learning Non-Industry Players: Drug Discovery and Diagnostics
Table 5.1 Advenio Technosys: Venture Capital Funding
Table 5.2 Advenio Technosys: Patent Portfolio
Table 5.3 AiCure: Venture Capital Funding
Table 5.4 AiCure: Patent Portfolio
Table 5.5 Atomwise: Key Partnerships
Table 5.6 Atomwise: Venture Capital Funding
Table 5.7 Atomwise: Patent Portfolio
Table 5.8 BenevolentAI: Venture Capital Funding
Table 5.9 Butterfly Network: Venture Capital Funding
Table 5.10 Butterfly Network: Patent Portfolio
Table 5.11 Enlitic: Venture Capital Funding
Table 5.12 Human Longevity: Partnerships and Collaborations
Table 5.13 Human Longevity: Venture Capital Funding
Table 5.14 Human Longevity: Patent Portfolio
Table 5.15 InSilico Medicine: Partnerships and Collaborations
Table 5.16 InSilico Medicine: Venture Capital Funding
Table 5.17 InSilico Medicine: Patent Portfolio
Table 5.18 twoXAR: Partnerships and Collaborations
Table 5.19 twoXAR: Venture Capital Funding
Table 5.20 Zebra Medical Vision: Partnerships and Collaborations
Table 5.21 Zebra Medical Vision: Venture Capital Funding
Table 5.22 Zebra Medical Vision: Patent Portfolio
Table 6.1 IBM: Artificial Intelligence Acquisitions
Table 6.2 Google: Artificial Intelligence Acquisitions
Table 6.3 IBM Watson: Collaborations & Partnerships in Healthcare
Table 6.4 Google DeepMind: Collaborations & Partnerships in Healthcare
Table 7.1 List of Funding Instances and Investors Involved
Table 7.2 Deep Learning in Drug Discovery & Diagnostics Market: Types of Funding, 2007-2016
Table 8.1 Opportunity for Deep Learning in Drug Discovery: Survey Responses
Table 8.2 Opportunity for Deep Learning in Drug Discovery: Forecast Parameters
Table 8.3 Deep Learning in Drug Discovery: Conservative Scenario, Key Parameters
Table 8.4 Deep Learning in Drug Discovery: Base Scenario Parameters
Table 8.5 Deep Learning in Drug Discovery: Optimistic Scenario Parameters
Table 9.1 Company Valuation Analysis: Sample Dataset
Table 9.2 Company Valuation Analysis: Weighted Average Evaluation
Table 9.3 Company Valuation Analysis: Estimated Valuation
Table 9.4 Company Valuation Analysis: Distribution by Specialization
Table 13.1 Deep Learning in Drug Discovery and Diagnostics: Distribution by Specialization
Table 13.2 Deep Learning in Drug Discovery and Diagnostics: Distribution by Service Provider Type
Table 13.3 Deep Learning in Drug Discovery and Diagnostics: Distribution by Geographical Location and Area of Specialization
Table 13.4 Deep Learning in Drug Discovery and Diagnostics: Distribution by Founding Year and Specialization
Table 13.5 Deep Learning in Drug Discovery: Distribution by Type of Solution
Table 13.6 Deep Learning in Drug Discovery: Distribution by Focus Area
Table 13.7 Deep Learning in Drug Discovery: Regional Mapping
Table 13.8 Deep Learning in Diagnostics: Distribution by Type of Solution
Table 13.9 Deep Learning in Diagnostics: Distribution by Type of Input Data
Table 13.10 Deep Learning in Diagnostics: Regional Mapping
Table 13.11 Deep Learning in Drug Discovery and Diagnostics: Regional Mapping
Table 13.12 Deep Learning in Drug Discovery and Diagnostics, Non-Industrial Players: Geographical Distribution
Table 13.13 IBM: Annual Revenues, 2011-Q3 2016 (USD Billion)
Table 13.14 Alphabet: Annual Revenues, 2011-Q3 2016 (USD Billion)
Table 13.15 IBM versus Google: Acquisition Trend (Artificial Intelligence), 2011-2016
Table 13.16 Funding Instances: Distribution by Year, 2007-2016
Table 13.17 Funding Instances: Distribution by Type of Funding, 2007-2016
Table 13.18 Funding Instances: Distribution by Total Amount Invested in Each Category, 2007-2016 (USD Million)
Table 13.19 Leading Companies: Evaluation by Number of Funding Instances
Table 13.20 Leading Companies: Evaluation by Number of Funding Instances
Table 13.21 Drug Approval: Historical Data, 2005-2015
Table 13.22 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Base Scenario (USD Billion)
Table 13.23 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Base Scenario (USD Billion)
Table 13.24 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Optimistic Scenario (USD Billion)
Table 13.25 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Optimistic Scenario (USD Billion)
Table 13.26 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Conservative Scenario (USD Billion)
Table 13.27 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Conservative Scenario (USD Billion)
Table 13.28 Deep Learning Market in Drug Discovery (2017-2035): Market Scenarios (USD Billion)
Table 13.29 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), High Income Countries
Table 13.30 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), Middle Income Countries
Table 13.31 Deep Learning in Diagnostics: Deep Learning Efficiency Profile
Table 13.32 Deep Learning Market in Diagnostics, Short-Midterm (2017-2026) (USD Billion)
Table 13.33 Deep Learning Market in Diagnostics, Long Term (2026-2035): Base Scenario (USD Billion)
Table 13.34 Deep Learning Market in Diagnostics: Market Distribution (USD Billion)
Table 13.35 Deep Learning Market in Diagnostics: Market Distribution (USD Billion)
Table 13.36 Company Valuation Analysis: Valuation Ratios, Input Dataset

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 23andMe
  • ClearView Diagnostics
  • gener8tor
  • Jvion
  • Notable Labs
  • Standigm
  • MORE

Deep learning is a novel machine learning technique that can be used to generate relevant insights from large volumes of data. The term Deep Learning was coined in 2006 by Geoffrey Hinton to refer to algorithms that enable computers to analyze objects and text in videos and images. Fundamentally, deep learning algorithms are designed to analyze and use large volumes of data to improve the capabilities of machines.

Companies, such as Google, Amazon, Facebook, LinkedIn, IBM and Netflix, are already using deep learning algorithms to analyze users’ activities and make customized suggestions and recommendations based on individual preferences. Today, in many ways, deep learning algorithms have enabled computers to see, read and write. In light of recent advances, the error rate associated with machines being able to analyze and interpret medical images has come down to 6%, which, some research groups claim, is even better than humans.

The applications of the technology are being explored across a variety of areas. Specifically in healthcare, the American Recovery and Reinvestment Act of 2009 and the Precision Medicine Initiative of 2015 have widely endorsed the value of medical data in healthcare. Owing to several such initiatives, medical big data is expected to grow approximately 50-fold to reach 25,000 petabytes by 2020. Since 80% of this is unstructured, it is difficult to generate valuable / meaningful insights using conventional data mining techniques. In such cases, deep learning has emerged as a novel solution. Lead identification and optimization in drug discovery, support in patient recruitment for clinical trials, medical image analysis, biomarker identification, drug efficacy analysis, drug adherence evaluation, sequencing data analysis, virtual screening, molecule profiling, metabolomic data analysis, EMR analysis and medical device data evaluation are examples of applications where deep learning based solutions are being explored.

The likely benefits associated with the use of deep learning based solutions in the above mentioned areas is estimated to be worth multi billion dollars. There are well-known references where deep learning models have accelerated the drug discovery process and provided solutions to precision medicine. With potential applications in drug repurposing and preclinical research, deep learning in drug discovery is likely to have great opportunity. In diagnostics, an increase in the speed of diagnosis is likely to have a profound impact in regions with large patient to physician ratios. The implementation of such solutions is anticipated to increase the efficiency of physicians providing a certain amount of relief to the overly-burdened global healthcare system.

Note: Product cover images may vary from those shown
5 of 5
  • 23andMe
  • Accel
  • Advenio Technosys
  • Aeris Capital
  • Agfa HealthCare
  • AiCure
  • AlchemyAPI
  • Alder Hey Children’s NHS Foundation Trust
  • Alexandria Real Estate Equities
  • AlgoSurg
  • Allen & Company
  • Almaworks
  • Alphabet
  • AltaIR Capital
  • Amazon
  • AME Cloud Ventures
  • American Cancer Society
  • American Diabetes Association
  • American Sleep Apnea Association
  • American Well
  • Amplify Partners
  • Analytics Ventures
  • Anne Arundel Medical Center
  • API.AI
  • Appistry
  • Apple
  • ARCH Venture Partners
  • Arterys
  • Arya.ai
  • Asian Institute of Public Health
  • Asset Management Ventures
  • AstraZeneca
  • Atlas Ventures
  • Atomwise
  • Avalon AI
  • Baptist Health
  • Bay Labs
  • Behold.ai
  • BenevolentAI
  • BERG Health
  • BEROCEUTICA
  • Beth Israel Deaconess Medical Center
  • Bill and Melinda Gates Foundation
  • Biogen
  • Biomatics Capital
  • BioTime
  • Bloomberg Beta
  • BlueCross BlueShield Venture Partners
  • Boston Children’s Hospital
  • Brighterion
  • Butterfly Network
  • Calico Labs
  • Cambia Health Solutions
  • CAMELOT biomedical systems
  • Capital One Growth Ventures
  • Capitol Health
  • Carestream Health
  • Carnegie Mellon University
  • Casdin Capital
  • Celgene
  • Centre for Addiction and Mental Health
  • ChemDiv
  • China Bridge Capital
  • Chinese University of Hong Kong
  • Claremont Creek Ventures
  • ClearView Diagnostics
  • Cleveland Clinic
  • Cleveland Clinic Lerner College of Medicine
  • Clever Sense
  • CLI Ventures
  • Clinithink
  • Cloud Pharmaceuticals
  • Cognea
  • ContextVision
  • Convertro
  • CorTech Labs
  • CRG
  • CureMetrix
  • Cyclica
  • Cyrcadia Health
  • Dark Blue Labs
  • Data Collective Venture Capital
  • Datamind
  • Deep 6 Analytics
  • Deep Genomics
  • DeepFork Capital
  • DeepKnowledge Ventures
  • Dell
  • Desktop Genetics
  • DHHS Health Care Innovation
  • Dimagi
  • DNNresearch
  • Dolby
  • Draper Associates
  • Eastern Virginia Medical School
  • Eastside Partners
  • Eleven Two Capital
  • Emergent Medical Partners
  • Emery Capital
  • Engineering Manufacturer Entrepreneurs Resource Group
  • Enlitic
  • Enterra Solutions
  • European Investment Bank
  • Eurovestech
  • Exigent Capital
  • Explorys
  • Facebook
  • Fidelity Management & Research
  • Finance Wales
  • Finnish Funding Agency for Innovation
  • First Round Capital
  • Fitbit
  • Flatiron Health
  • Flipkart
  • Formation 8
  • Foundation Capital
  • Founders Fund
  • Freenome
  • Froedtert & the Medical College of Wisconsin Cancer Network
  • Frost Data Capital
  • Gachon University Gil Medical Center
  • GE Healthcare
  • GE Ventures
  • Genentech
  • gener8tor
  • Genesis Capital Advisors
  • Gi Global Health Fund
  • Gigaom
  • Globavir Biosciences
  • Google
  • Google DeepMind
  • Google Ventures
  • Granata Decision Systems
  • Grand Challenges Canada
  • Gravity
  • Great Oaks Capital
  • GSK
  • H20.ai
  • Hangzhou Cognitive Care
  • Hanmi Science
  • Harvard Medical School
  • Harvard University
  • Healthbox
  • HelpAround
  • Hera Fund
  • Heritage Provider Network
  • Hologic
  • Howard University Hospital
  • Huazhong University of Science and Technology
  • Human Longevity
  • Hummingbird Bioscience
  • IA Ventures
  • iBinom
  • IBM
  • Icahn School of Medicine at Mount Sinai
  • iCarbonX
  • ifa systems
  • IIM Ahmedabad
  • Illumina
  • Imagia Cybernetics
  • Imaging Advantage
  • Imperial College London
  • Indian Institute of Technology Bombay
  • Indisys
  • Infermedica
  • Infosys
  • Inoveon corporation
  • InSilico Medicine
  • InSilicoScreen
  • Intel
  • Intel Capital
  • Intermountain Healthcare
  • IQ Capital Partners
  • IQbility
  • iSono Health
  • J Craig Venter Institute
  • Jetpac
  • Johnson & Johnson
  • Jvion
  • K Cube Ventures
  • Karlin Ventures
  • Keshif Ventures
  • Kheiron Medical
  • Khosla Ventures
  • King’s College London
  • Kstart
  • La Costa Investment Group
  • Laboratory Corporation of America
  • LAM Therapeutics
  • Lanza techVentures
  • LETA Capital
  • LifeExtension
  • Lightspeed Venture Partners
  • Lilly Ventures
  • London Business Angels
  • London Co-Investment Fund
  • Lumiata
  • Lunit
  • Lux Capital
  • Maccabi Healthcare Services
  • Magic Pony
  • Manipal Hospital
  • Martin Ventures
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medtronic
  • MedyMatch Technology
  • Merck
  • Merge Healthcare
  • Metabolon
  • Methinks Software
  • Microsoft
  • Mind the Byte
  • Mindshare Medical
  • Mitsui
  • Mohr Davidow Ventures
  • Molplex Pharmaceuticals
  • Moodstocks
  • Moorfields Eye Hospital
  • Morado Venture Partners
  • MPM Capital
  • Mumkin Hai
  • National Center for Advancing Translational Sciences
  • National Center for Research Resources
  • National Institute of Research for Tuberculosis
  • National Institute on Drug Abuse
  • National Institutes of Health
  • National Neonatology Forum of India
  • National Science Foundation
  • Nazarbayev University
  • Nervana Systems
  • New Enterprise Associates
  • New Leaf Venture Partners
  • New York Genome Center
  • Next IT Healthcare
  • Nexus Venture Partners
  • nference
  • Norwich Ventures
  • Notable Labs
  • Novartis
  • Novo Nordisk
  • Numedii
  • Numerate
  • NVIDIA
  • ODH Solutions
  • Optellum
  • Organic Research Corporation
  • OS Fund
  • Ovuline
  • Owkin
  • Park City Angel Network
  • PathAI
  • Pathway Genomics
  • Paxion Capital Partners
  • Peak Ventures
  • PerrWell
  • Personal Genome Diagnostics
  • Pfizer
  • Pharmatics
  • Phytel
  • Piraeus Jeremie Technology Catalyst Fund
  • Polaris Partners
  • Prime Health Care Services
  • Pritzker Group
  • Proteus Digital Health
  • Proximagen
  • Quest Diagnostics
  • QuikFlo Health
  • Radiology Associates of South Florida
  • Realize Ai
  • Reno Angels
  • ReviveMed Technologies
  • Rhön-Klinikum Hospitals
  • Roche
  • RSIP Vision
  • Salesforce
  • Salt Lake Life Sciences Angels
  • Samsung
  • Sandbox Industries
  • SemanticMD
  • Sentara Healthcare
  • Sentient Technologies
  • Seven Peak Ventures
  • Sheridan Healthcare
  • SickKids
  • Siemens Healthineers
  • SigTuple
  • Slow Ventures
  • SoftBank Ventures Korea
  • SolveBio
  • Southern Ontario Smart Computing Innovation Platform
  • SPARK Impact
  • SparkBeyond
  • SRI Ventures
  • SRL Diagnostics
  • Standigm
  • Stanford School of Medicine
  • Stanford University
  • StartX
  • SV Angel
  • Synthetic Genomics
  • Tailormed Technologies
  • TellApart
  • Tencent
  • Teva Pharmaceutical
  • The Indus Entrepreneurs
  • The Royal Free London NHS Foundation Trust
  • The Scripps Research Institute
  • The University of Chicago
  • Third Kind Venture Capital
  • Tianfu Group
  • Tiatros
  • Timeful
  • Tomocube
  • Topcon
  • Toth Technology
  • Transamerica
  • Tribeca Venture Partners
  • True Ventures
  • Truven Health Analytics
  • Twitter
  • Two Sigma Ventures
  • twoXAR
  • Under Armour
  • Universe Ventures
  • University College London Hospital NHS Trust
  • University of Calgary
  • University of California
  • University of Miami Health System
  • University of Michigan
  • University of Montreal
  • University of Oxford
  • University of Pittsburgh
  • University of San Diego Medical Center
  • University of Sheffield
  • University of Texas Health Science Center
  • University of the Philippines
  • University of Toronto
  • University of Vermont Health Network
  • Vanguard Atlantic
  • Vcanbio Cell & Gene Engineering Corporation
  • VentureNursery
  • Verge Genomics
  • VisExcell
  • Vision Factory
  • Vision Genomics
  • Vium
  • Viv
  • vRad (Virtual Radiologic)
  • VUNO
  • WellPoint
  • Wildcard Pharmaceutical Consulting
  • Wilmington Pharmatech
  • Woodford Investment Management
  • WuXi Healthcare Ventures
  • Wuxi NextCODE
  • Xfund
  • Y Combinator
  • YourNest Angel Fund
  • Zebra Medical Vision
  • Zhongyuan Union
  • Zone Startups India
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll